Key result
Female patients with stage C/D chronic heart failure had a significantly reduced risk of all-cause mortality compared to male patients after adjustment for clinical variables (adjusted HR 0.791).
Why the study?
Do clinical characteristics, treatment, and long-term outcomes differ between female and male patients with Stage C/D heart failure?
Population
4,736 consecutive chronic heart failure patients in stage C/D out of 10,219 patients registered in the…
Comparison
Female gender (observational exposure) vs Male gender
Design
Cohort
Follow-up
median 3.1 years
Authors
Loading...
Women with stage C/D HF had lower adjusted mortality risk; leaves open whether sex-specific management improves outcomes.
Observational (n=4,736)
Yes
Do clinical characteristics, treatment, and long-term outcomes differ between female and male patients with Stage C/D heart failure?
Hazard Ratio: 0.791 (95% CI 0.64–0.979)
Absolute Event Rate: 52.4% vs 47.3%
p-value: p=0.031
In Japanese patients with Stage C/D heart failure, women have a lower adjusted risk of all-cause mortality compared to men, despite presenting with more severe clinical manifestations and receiving less evidence-based medical therapy.
Sakata et al. (2013) conducted an observational in Stage C/D Chronic Heart Failure (n=4,736). Female gender vs. Male gender was evaluated on All-cause mortality (Adjusted HR 0.791, 95% CI 0.640-0.979, p=0.031). Female patients with stage C/D chronic heart failure had a significantly reduced risk of all-cause mortality compared to male patients after adjustment for clinical variables (adjusted HR 0.791).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: